Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 11/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11141024 | 0.89 | ACHE (0.52) | L3MBTL1ACHELMNASMN1; SMN2KMT2A | |
| SCHEMBL27357775 | 0.87 | ACHE (0.47) | L3MBTL1ACHELMNASMN1; SMN2KMT2A | |
| SCHEMBL27357778 | 0.87 | ACHE (0.47) | L3MBTL1ACHELMNASMN1; SMN2KMT2A | |
| SCHEMBL26460411 | 0.87 | ACHE (0.47) | L3MBTL1ACHELMNASMN1; SMN2KMT2A | |
| SCHEMBL1064714 | 0.86 | ACHE (0.42) | L3MBTL1ACHELMNASMN1; SMN2KMT2A | |
| SCHEMBL1065642 | 0.86 | ACHE (0.42) | L3MBTL1ACHELMNASMN1; SMN2KMT2A | |
| SCHEMBL24854772 | 0.85 | ACHE (0.50) | L3MBTL1ACHELMNASMN1; SMN2KMT2A | |
| SCHEMBL30786561 | 0.85 | ACHE (0.57) | ACHETLR2 | |
| SCHEMBL30733875 | 0.85 | ACHE (0.57) | ACHETLR2 | |
| SCHEMBL30786562 | 0.85 | ACHE (0.57) | ACHETLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297768-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THERAPEUTIC USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-10-13 | — | — | US | disclosed |
| US-8163791-B2 | Imidazole derivatives that induce apoptosis and their therapeutic uses | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2012-04-24 | — | — | US | disclosed |
| US-8163791-B2 | Imidazole derivatives that induce apoptosis and their therapeutic uses | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2012-04-24 | — | — | US | disclosed |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | NFATC1, AIFM1, TP53 | L3MBTL1 1325/4885ACHE 4409/4885LMNA 753/4885 |
| US-20160297768-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THERAPEUTIC USE THEREOF | TP53, BAD, API5 | L3MBTL1 3151/4885ACHE 4837/4885LMNA 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.